Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (Stem Cells Arabia)
- Development stage
- Unknown
- Lead developer
- Stem Cells Arabia
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
Autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) developed by Stem Cells Arabia are an experimental cell therapy investigated for the treatment of relapsing-remitting multiple sclerosis (RRMS). The therapeutic process involves harvesting a patient's own bone marrow, followed by the isolation and expansion of specific stem cell populations, primarily mesenchymal stem cells. These cells are then re-administered to the patient via both intravenous and intrathecal routes. The mechanism of action is primarily based on the immunomodulatory properties of MSCs, which secrete a variety of anti-inflammatory cytokines and neurotrophic factors. These secretions aim to suppress the aberrant autoimmune response responsible for neuroinflammation and axonal damage in MS, while potentially creating a microenvironment conducive to endogenous re-myelination and neural repair.
- Other names
- BM-MSCautologous bone marrow-derived stem cellsStem Cell Transplantation (Stem Cells Arabia)
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (Stem Cells Arabia).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (Stem Cells Arabia).